Briefing documents for Tuesday's meeting of the FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) showed reviewers are unconvinced about Vertex Pharmaceuticals Inc.'s Orkambi, which consists of the firm's already approved Kalydeco (ivacaftor) and lumacaftor combined for homozygous F508del cystic fibrosis (CF) patients.